Spark Therapeutics, Inc. (NASDAQ:ONCE) has been assigned a consensus rating of “Buy” from the sixteen analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $84.13.
A number of equities research analysts recently issued reports on ONCE shares. William Blair started coverage on shares of Spark Therapeutics in a research note on Wednesday, June 28th. They issued an “outperform” rating on the stock. ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $60.00 to $100.00 in a research note on Tuesday. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 9th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $92.00 price target (up previously from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd.
ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/12/brokerages-set-spark-therapeutics-inc-nasdaqonce-target-price-at-73-83-updated-updated-updated.html.
Spark Therapeutics (NASDAQ ONCE) opened at 75.96 on Friday. The stock’s market cap is $2.37 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $80.89. The stock has a 50 day moving average of $67.15 and a 200 day moving average of $59.85.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same period in the prior year, the business posted ($1.04) EPS. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year. On average, equities research analysts anticipate that Spark Therapeutics will post ($7.49) earnings per share for the current fiscal year.
In other news, General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00. Following the transaction, the general counsel now owns 9,567 shares in the company, valued at approximately $526,185. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of Spark Therapeutics stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $80.01, for a total value of $2,292,286.50. Following the transaction, the chief executive officer now owns 258,650 shares in the company, valued at approximately $20,694,586.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 314,310 shares of company stock worth $21,866,838. Insiders own 7.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC raised its position in Spark Therapeutics by 109.9% in the second quarter. Virtu KCG Holdings LLC now owns 13,110 shares of the biotechnology company’s stock valued at $783,000 after buying an additional 6,863 shares in the last quarter. California Public Employees Retirement System raised its position in Spark Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock valued at $2,336,000 after buying an additional 800 shares in the last quarter. Vanguard Group Inc. raised its position in Spark Therapeutics by 5.3% in the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after buying an additional 96,803 shares in the last quarter. Northern Trust Corp raised its position in Spark Therapeutics by 17.7% in the second quarter. Northern Trust Corp now owns 287,458 shares of the biotechnology company’s stock valued at $17,172,000 after buying an additional 43,199 shares in the last quarter. Finally, Citigroup Inc. raised its position in Spark Therapeutics by 178.0% in the second quarter. Citigroup Inc. now owns 73,951 shares of the biotechnology company’s stock valued at $4,418,000 after buying an additional 47,347 shares in the last quarter. Institutional investors and hedge funds own 88.95% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.